Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, Galapagos' most advanced novel mode-of-action program, was discovered using our proprietary target discovery technology, and is being developed by Gilead and Galapagos in several inflammatory indications. Galapagos is progressing multiple programs in inflammation, cystic fibrosis, metabolic diseases, fibrosis, and other disease areas. Galapagos is listed on Euronext Amsterdam and Brussels and on the NASDAQ; all with the ticker symbol GLPG. Source
No articles found.
Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committ...
Verastem Oncology (Nasdaq: VSTM) is a commercia...
Forward Pharma A/S is a Danish biopharmaceutical company that commenced developmen...
Forward Pharma A/S is a Danish biopharmaceutica...
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
Horizon is a biopharmaceutical company focused on researching, developing and comm...
Horizon is a biopharmaceutical company focused ...
Edesa Biotech Inc. is a clinical-stage biopharmaceutical company founded by expert...
Edesa Biotech Inc. is a clinical-stage biopharm...
Osmotica Pharmaceuticals plc is a fully-integrated biopharmaceutical company focus...
Osmotica Pharmaceuticals plc is a fully-integra...
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...
Dynavax Technologies Corporation (Nasdaq: DVAX)...
Join the National Investor Network and get the latest information with your interests in mind.